# Statin-Associated Myositis in a High-Risk Cardiovascular Patient: Challenges in Reintroducing Therapy

## TL;DR

This paper discusses the challenges of managing statin-induced muscle symptoms in a high-risk cardiovascular patient.

## Contribution

The paper presents a case study highlighting the complexities of managing statin-associated myositis in patients with multiple comorbidities.

## Key findings

- Statin-associated muscle symptoms can lead to discontinuation of therapy in high-risk patients.
- Alternative lipid-lowering strategies like PCSK9 inhibitors may be necessary when statins are not tolerated.

## Abstract

Statin-associated muscle symptoms (SAMS) are a common side effect of statin therapy, which is widely used to manage cardiovascular diseases (CVDs). These symptoms, which can range from mild muscle discomfort to more severe complications, may lead some patients to discontinue statin therapy, potentially affecting cardiovascular risk management. We present the case of a 67-year-old male patient with multiple cardiovascular comorbidities, including peripheral artery disease (PAD), who developed SAMS after resuming rosuvastatin. Management included statin discontinuation, supportive care with intravenous fluids, and transition to a non-statin lipid-lowering agent (proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor). This case highlights the diagnostic and therapeutic challenges of managing SAMS in a patient with complex cardiovascular comorbidities, particularly focusing on distinguishing myopathy from ischemic symptoms and navigating statin reintroduction versus alternative lipid-lowering strategies.